Though much of the current innovation in the healthcare field is aimed at speeding up time to diagnosis, it can still take days or even weeks of waiting for test results and genetic analyses to come through before patients receive definitive answers about mysterious health conditions.
Pacific Biosciences will work with machine learning researchers at Google to bolster the accuracy of its DNA sequencing hardware.
After spending the past few years laying the groundwork for a full-scale launch of its KidneyIntelX technology, Renalytix is predicting that “2022 is going to be a heavy year of milestones,” CEO James McCullough said during a presentation at the J.P. Morgan Healthcare Conference Wednesday.
The buildup of fatty substances on the artery walls, known as atherosclerosis, involves inflammatory processes and can cause various cardiovascular diseases. Now, scientists at the La Jolla Institute for Immunology (LJI) have shed light on how targeting garbage-cleaning immune cells called macrophages might reverse or prevent the clogging problem.
The European Medicines Agency (EMA) wants to speed up your clinical trials. Through the Accelerating Clinical Trials in the EU (ACT EU) initiative, the EMA and other bodies have set out (PDF) 10 actions they plan to prioritize in 2022 and 2023 to transform how studies are initiated, designed and run.
FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish
Mithra has brushed off a missed co-primary endpoint in one of its two phase 3 clinical trials and given a bullish update (PDF) on the menopause drug, which it expects to gain a global partner this year and go on to win approval on both sides of the Atlantic in 2024. Shares in the Belgian biotech rose 9% to around 22 euros ($25).
After dropping a late-stage asset and hitting an FDA roadblock in the JAK inhibitor class last year, Galapagos is in need of a 2022 rebound. With active discussions underway at the J.P. Morgan Healthcare Conference to find an acquisition target and a new CEO expected within weeks, the biopharma is trying to spark a revival.
Artificial-intelligence-powered molecule designer Insilico Medicine has collected another international drug discovery partnership, with the Shanghai-based Fosun Pharma signing on for work on four disease targets.
Philips spent the bulk of 2021 scrambling to mitigate the effects of the far-reaching recall of many of its CPAP and BiPAP machines and other respiratory devices. Unfortunately for the Dutch devicemaker, those issues appear poised to hamper its business into 2022, too.
Editas, which caught flak in 2021 for limited gene editing data, will try to layer on the proof in 2022
Editas Medicine released a tiny drop of data last year as a proof of concept for its gene editing platform. Now, the CRISPR/Cas9 biotech will spend 2022 trying to back that up.